The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 349:1087-1088 September 11, 2003 Number 11
NextNext

Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Meis, P. J.
-PubMed Citation
To the Editor: After reading the article by Meis et al. (June 12 issue),1 we strongly discourage practitioners from using 17 alpha-hydroxyprogesterone caproate in the care of women who have had preterm deliveries, until more investigation is done.

Although initially enthusiastic about the results, which showed a risk reduction among the women who received 17 alpha-hydroxyprogesterone caproate, we were concerned about the high rate of recurrent preterm delivery among the women who received placebo. The Methods section states that the placebo was castor oil. Ricinoleic acid, the active ingredient in castor oil, is a known uterine stimulant.2,3 Castor oil is . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.